Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer

NCT05215379 | Completed Phase 2

• 1 other identifier: CHCRS-Immunity
• Study Type: interventional
• Target: 201
• Locations: 1 country
• Sites: 1

Brief Summary

At present, there are no relevant studies or reports on the effect of neoadjuvant chemoradiation therapy combined with immunotherapy for MSS ultra-low rectal cancer. Studied in this paper combin neoadjuvant chemoradiation with immune therapy, carry out "Multicenter prospective randomized clinical trial of neoadjuvant chemoradiation therapy combined with immunotherapy for MSS ultra-low rectal cancer" in order to provide a high-level evidence-based medical evidence for ultra-low rectal cancer treatment and improve ultra-low rectal cancer diagnosis and treatment effect.

Conditions

Neoadjuvant Chemoradiation Therapy; Rectal Cancer; Immunotherapy; Microsatellite Instability Low

Outcome Measures

Primary Outcomes (1)

• The rate of cCR

  Rate of patients who achieve clinical complete response

  2 years

Secondary Outcomes (6)

• The rate of organ preservation

  2 years

• The rate of anus preservation

  2 years

• pCR rate

  2 years

• Disease free survival(DFS)

  2 years

• overall survival(OS)

  2 years

Study Arms (2)

neoadjuvant chemoradiation therapy

OTHER

neoadjuvant chemoradiation therapy

Other: Control

neoadjuvant chemoradiation therapy +immunotherapy

EXPERIMENTAL

neoadjuvant chemoradiation therapy +immunotherapy

Drug: xintilimab injection

Interventions

xintilimab injection DRUG

neoadjuvant chemoradiation therapy +xintilimab injection 200mg/3week 4cycle

neoadjuvant chemoradiation therapy +immunotherapy

Control OTHER

neoadjuvant chemoradiation therapy

neoadjuvant chemoradiation therapy

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Ultra low rectal cancer patients evaluated by multidisciplinary team to perform APR
• Patients who have a strong desire to preserve the anus and are willing to accept neoadjuvant treatment
• years old ≤ age ≤ 75 years old, no gender limit;
• Colonoscopy, intracavitary ultrasound and pelvic high-resolution MRI (or enhanced CT) were diagnosed as extremely low rectal cancer within 5 cm from the lower edge of the tumor to the anal edge. The baseline clinical stage is T1-3aN0-1M0, and the size of the tumor \<1/2 circle;
• Histopathological diagnosis of rectal adenocarcinoma; tumor biopsy immunohistochemistry showed pMMR, that is, MSH1, MSH2, MSH6 and PMS2 four proteins are positive, or genetic testing suggests MSI-L or MSS.
• The patient has good compliance and can come to the hospital for reexamination as required;
• ECOG physical status score 0-1 points;
• Have not received anti-tumor and immunotherapy before being selected;
• \. Laboratory inspections must meet the following standards: i. White blood cell count ≥3.5×109/L, absolute neutrophil count ≥1.8×109/L, platelet count ≥100×10\^9/L, hemoglobin ≥100g/L; ii. INR≤1.5, and APTT≤1.5 times the upper limit of normal value or partial prothrombin time (PTT)≤1.5 times the upper limit of normal value; iii. Total bilirubin≤1.25 times the upper limit of normal; ALT and AST≤5 times the upper limit of normal; iv. 24h creatinine clearance rate ≥50mL/min or blood creatinine ≤1.5 times the upper limit of normal.
• Voluntarily sign the informed consent form;

You may not qualify if:

• History of other malignant diseases in the past 5 years;
• Patients with metastases ;
• Patients with intestinal obstruction, intestinal perforation, intestinal bleeding, etc. who need emergency surgery;
• Those who are known to be allergic to capecitabine, oxaliplatin, PD-1 monoclonal antibody and other drugs;
• Patients with poorly differentiated adenocarcinoma, signet ring cell carcinoma, and mucinous adenocarcinoma;
• The patient is accompanied by any unstable systemic diseases, including but not limited to: severe infection, uncontrolled diabetes, hypertension that cannot be controlled by drugs, unstable angina, cerebrovascular accident or transient cerebral ischemia, myocardium Infarction, congestive heart failure, severe arrhythmia requiring medication, liver, kidney or metabolic diseases; diseases that affect the life of the patient.
• The patient's accompanying diseases (such as mental illness, etc.) or conditions (such as alcohol or drug abuse, etc.) will increase the patient's risk of receiving experimental drug treatment or affect the patient's compliance with the trial requirements, or may confuse the research results;
• Within 30 days before screening, the patient has received any other experimental drug treatment or participated in another interventional clinical trial;
• Women who are pregnant or breastfeeding or who intend to become pregnant or breastfeeding during the study period; men or women who are unwilling to take effective contraceptive measures;
• The investigator judges that the patient is not suitable to participate in other situations such as the clinical trial.

Sponsors & Collaborators

• Changhai Hospital: lead

Study Sites (1)

Department of Colorectal Surgery in Changhai Hospital

Shanghai, Shanghai Municipality, 200433, China

Location

Related Publications (1)

• Zhou L, Yu G, Wen R, Jia H, Zhang T, Peng Z, Fan H, Pan A, Yu Y, Zhu X, Gong H, Gao X, Lou Z, Zhang W. Neoadjuvant chemoradiation therapy combined with immunotherapy for microsatellite stable ultra-low rectal cancer (CHOICE II): study protocol of a multicentre prospective randomised clinical trial. BMJ Open. 2023 Sep 13;13(9):e069793. doi: 10.1136/bmjopen-2022-069793.

  PMID: 37709314 DERIVED

MeSH Terms

Conditions

Rectal Neoplasms

Condition Hierarchy (Ancestors)

Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Intestinal Diseases; Rectal Diseases

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief physician, professor

Study Record Dates

• First Submitted: January 5, 2022
• First Posted: January 31, 2022
• Study Start: October 1, 2022
• Primary Completion: December 30, 2024
• Study Completion: June 24, 2025
• Last Updated: January 2, 2026

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: 2 years

Locations

CN (1)